两种实时荧光定量PCR装置对CYP2C19药物遗传学结果分析的相关性

IF 2.3 Q3 PHARMACOLOGY & PHARMACY
Alba Alonso Llorente, Josefa Salgado Garrido, Oscar Teijido Hermida, Fabricio González Andrade, Alberto Valiente Martín, Ana Fanlo Villacampa, Jorge Vicente Romero
{"title":"两种实时荧光定量PCR装置对CYP2C19药物遗传学结果分析的相关性","authors":"Alba Alonso Llorente, Josefa Salgado Garrido, Oscar Teijido Hermida, Fabricio González Andrade, Alberto Valiente Martín, Ana Fanlo Villacampa, Jorge Vicente Romero","doi":"10.3390/scipharm91040051","DOIUrl":null,"url":null,"abstract":"CYP2C19 is a highly polymorphic gene responsible for the metabolism of commonly used drugs. CYP2C19*1, the wild-type allele, is associated with normal enzyme activity, whereas CYP2C19*2 and CYP2C19*17 lead to null and increased enzyme activity, respectively. The use of different instruments to perform the same pharmacogenetic tests should not affect the reliability of the results reported to clinicians, as required by the ISO 15189 standard. Genotyping assays allowed for the identification of gene variants corresponding to the CYP2C19*2 and CYP2C19*17 haplotypes in 44 selected samples. Each sample was analyzed in duplicate using the Thermo Fisher Taqman Drug Metabolism probes CYP2C19*2: c_25986767_70 (rs4244285) and CYP2C19*17: c_469857_10 (rs12248560). The experiments were performed on two widely used types of real-time PCR analyzers: ABI PRSIM™7500 and QuantStudioTM12KFlex (both from Applied Biosystems, Thermofisher). The data were analyzed in a Thermo Fisher Cloud facility. The analysis was performed independently by two qualified professionals. Both different instruments and analysts’ interpretations were consistent in identifying the native homozygous, heterozygous, and mutant homozygous variants for CYP2C19*2 and CYP2C19*17. The results provided by both the primary and backup analyzers showed a perfect correlation. This would allow for the use of the backup analyzer in case the main one is not available.","PeriodicalId":21601,"journal":{"name":"Scientia Pharmaceutica","volume":"20 2","pages":"0"},"PeriodicalIF":2.3000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Correlation of Two Different Real-Time PCR Devices for the Analysis of CYP2C19 Pharmacogenetic Results\",\"authors\":\"Alba Alonso Llorente, Josefa Salgado Garrido, Oscar Teijido Hermida, Fabricio González Andrade, Alberto Valiente Martín, Ana Fanlo Villacampa, Jorge Vicente Romero\",\"doi\":\"10.3390/scipharm91040051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"CYP2C19 is a highly polymorphic gene responsible for the metabolism of commonly used drugs. CYP2C19*1, the wild-type allele, is associated with normal enzyme activity, whereas CYP2C19*2 and CYP2C19*17 lead to null and increased enzyme activity, respectively. The use of different instruments to perform the same pharmacogenetic tests should not affect the reliability of the results reported to clinicians, as required by the ISO 15189 standard. Genotyping assays allowed for the identification of gene variants corresponding to the CYP2C19*2 and CYP2C19*17 haplotypes in 44 selected samples. Each sample was analyzed in duplicate using the Thermo Fisher Taqman Drug Metabolism probes CYP2C19*2: c_25986767_70 (rs4244285) and CYP2C19*17: c_469857_10 (rs12248560). The experiments were performed on two widely used types of real-time PCR analyzers: ABI PRSIM™7500 and QuantStudioTM12KFlex (both from Applied Biosystems, Thermofisher). The data were analyzed in a Thermo Fisher Cloud facility. The analysis was performed independently by two qualified professionals. Both different instruments and analysts’ interpretations were consistent in identifying the native homozygous, heterozygous, and mutant homozygous variants for CYP2C19*2 and CYP2C19*17. The results provided by both the primary and backup analyzers showed a perfect correlation. This would allow for the use of the backup analyzer in case the main one is not available.\",\"PeriodicalId\":21601,\"journal\":{\"name\":\"Scientia Pharmaceutica\",\"volume\":\"20 2\",\"pages\":\"0\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scientia Pharmaceutica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/scipharm91040051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientia Pharmaceutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/scipharm91040051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

CYP2C19是一个高度多态性的基因,负责常用药物的代谢。野生型等位基因CYP2C19*1与正常酶活性相关,而CYP2C19*2和CYP2C19*17分别导致酶活性为零和增加。按照ISO 15189标准的要求,使用不同的仪器进行相同的药物遗传学试验不应影响向临床医生报告结果的可靠性。通过基因分型分析,在44个样本中鉴定出CYP2C19*2和CYP2C19*17单倍型对应的基因变异。每个样品使用赛默飞世尔Taqman药物代谢探针CYP2C19*2: c_25986767_70 (rs4244285)和CYP2C19*17: c_469857_10 (rs12248560)进行重复分析。实验在两种广泛使用的实时PCR分析仪上进行:ABI PRSIM™7500和QuantStudioTM12KFlex(均来自Thermofisher应用生物系统公司)。数据在赛默飞世尔云设施中进行分析。分析由两名合格的专业人员独立进行。在鉴定CYP2C19*2和CYP2C19*17的原生纯合、杂合和突变纯合变体时,不同的仪器和分析人员的解释是一致的。主分析仪和备用分析仪提供的结果显示完全相关。这将允许在主分析器不可用的情况下使用备份分析器。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Correlation of Two Different Real-Time PCR Devices for the Analysis of CYP2C19 Pharmacogenetic Results
CYP2C19 is a highly polymorphic gene responsible for the metabolism of commonly used drugs. CYP2C19*1, the wild-type allele, is associated with normal enzyme activity, whereas CYP2C19*2 and CYP2C19*17 lead to null and increased enzyme activity, respectively. The use of different instruments to perform the same pharmacogenetic tests should not affect the reliability of the results reported to clinicians, as required by the ISO 15189 standard. Genotyping assays allowed for the identification of gene variants corresponding to the CYP2C19*2 and CYP2C19*17 haplotypes in 44 selected samples. Each sample was analyzed in duplicate using the Thermo Fisher Taqman Drug Metabolism probes CYP2C19*2: c_25986767_70 (rs4244285) and CYP2C19*17: c_469857_10 (rs12248560). The experiments were performed on two widely used types of real-time PCR analyzers: ABI PRSIM™7500 and QuantStudioTM12KFlex (both from Applied Biosystems, Thermofisher). The data were analyzed in a Thermo Fisher Cloud facility. The analysis was performed independently by two qualified professionals. Both different instruments and analysts’ interpretations were consistent in identifying the native homozygous, heterozygous, and mutant homozygous variants for CYP2C19*2 and CYP2C19*17. The results provided by both the primary and backup analyzers showed a perfect correlation. This would allow for the use of the backup analyzer in case the main one is not available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scientia Pharmaceutica
Scientia Pharmaceutica Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.60
自引率
4.00%
发文量
67
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信